Literature DB >> 15300478

Atypical relapse of hemolytic uremic syndrome after transplantation.

Karolien H Olie1, Sandrine Florquin, Jaap W Groothoff, René Verlaak, Lisa Strain, Timothy H J Goodship, Jan J Weening, Jean-Claude Davin.   

Abstract

Atypical hemolytic uremic syndrome (HUS) frequently leads to end-stage renal failure and can relapse after transplantation. A 12-year-old girl presenting with familial atypical HUS with a factor H mutation was successfully transplanted 6 years after a first transplant that had failed because of immediate recurrent HUS. Prophylactic plasma exchange before and after transplantation was used. Two months after transplantation, concomitant with a reduction in plasma exchange frequency, the plasma creatinine increased from 70 micro mol/l to 194 micro mol/l in 2 weeks without thrombocytopenia or signs of hemolytic anemia. The patient had minimal clinical symptoms and a presumptive diagnosis of graft rejection was made. Despite treatment with six daily pulses of methylprednisolone, plasma creatinine continued to increase and a graft biopsy was therefore undertaken. This showed the typical appearance of a thrombotic microangiopathy without any evidence of rejection. Despite daily plasmapheresis and replacement of cyclosporine with tacrolimus, there was no improvement and transplant nephrectomy was undertaken. This patient demonstrates that HUS can recur in a kidney transplant without the diagnostic hematological features and emphasizes the need for early transplant biopsy in such patients showing a decline in transplant function.

Entities:  

Mesh:

Year:  2004        PMID: 15300478     DOI: 10.1007/s00467-004-1565-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.

Authors:  Giuseppe Remuzzi; Piero Ruggenenti; Daniela Codazzi; Marina Noris; Jessica Caprioli; Giuseppe Locatelli; Bruno Gridelli
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

2.  Post-transplant hemolytic-uremic syndrome.

Authors:  Piero Ruggenenti
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

3.  The successful treatment of atypical hemolytic uremic syndrome with plasmapheresis.

Authors:  W L Robson; A K Leung
Journal:  Clin Nephrol       Date:  1991-03       Impact factor: 0.975

4.  Recurrence of hemolytic uremic syndrome in renal transplant recipients.

Authors:  D Hebert; R K Sibley; S M Mauer
Journal:  Kidney Int Suppl       Date:  1986-07       Impact factor: 10.545

5.  Plasmapheresis in a very young infant with atypical hemolytic uremic syndrome.

Authors:  D Magen; A Oliven; Y Shechter; R Elhasid; G Bar-Joseph; I Zelikovic
Journal:  Pediatr Nephrol       Date:  2001-01       Impact factor: 3.714

6.  Plasma therapy in von Willebrand factor protease deficiency.

Authors:  Georges Deschênes; Agnès Veyradier; Sylvie Cloarec; Stéphane Benoit; Isabelle Desbois; Yves Gruel; Hubert Nivet
Journal:  Pediatr Nephrol       Date:  2002-08-16       Impact factor: 3.714

7.  Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus.

Authors:  K A Abraham; M A Little; A M Dorman; J J Walshe
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

8.  Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  A Quan; E K Sullivan; S R Alexander
Journal:  Transplantation       Date:  2001-08-27       Impact factor: 4.939

9.  Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis.

Authors:  D Ducloux; J M Rebibou; S Semhoun-Ducloux; M Jamali; V Fournier; C Bresson-Vautrin; J M Chalopin
Journal:  Transplantation       Date:  1998-05-27       Impact factor: 4.939

10.  Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.

Authors:  H P H Neumann; M Salzmann; B Bohnert-Iwan; T Mannuelian; C Skerka; D Lenk; B U Bender; M Cybulla; P Riegler; A Königsrainer; U Neyer; A Bock; U Widmer; D A Male; G Franke; P F Zipfel
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

View more
  11 in total

1.  Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review.

Authors:  Omar Al Ustwani; James Lohr; Grace Dy; Charles Levea; Gregory Connolly; Pradeep Arora; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2014-02

2.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

3.  Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Authors:  Samhar I Al-Akash; P Stephen Almond; Van H Savell; Salam I Gharaybeh; Cris Hogue
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

Review 4.  Renal transplantation in HUS patients with disorders of complement regulation.

Authors:  Lothar Bernd Zimmerhackl; Johanna Scheiring; Friederike Prüfer; C Mark Taylor; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

5.  Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.

Authors:  Jon Jin Kim; Tim H J Goodship; Jane Tizard; Carol Inward
Journal:  Pediatr Nephrol       Date:  2011-06-30       Impact factor: 3.714

6.  Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Lapeyraque; Véronique Frémeaux-Bacchi; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

Review 7.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

Review 8.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

9.  Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options.

Authors:  Sudarsana De; Aoife M Waters; Audrey O Segal; Agnes Trautmann; Elizabeth A Harvey; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2009-10-24       Impact factor: 3.714

10.  Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.

Authors:  Jean Claude Davin; Lisa Strain; Tim H J Goodship
Journal:  Pediatr Nephrol       Date:  2008-05-16       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.